204 related articles for article (PubMed ID: 32278856)
1. Targeting STAT3 in cancer and autoimmune diseases.
Gharibi T; Babaloo Z; Hosseini A; Abdollahpour-Alitappeh M; Hashemi V; Marofi F; Nejati K; Baradaran B
Eur J Pharmacol; 2020 Jul; 878():173107. PubMed ID: 32278856
[TBL] [Abstract][Full Text] [Related]
2. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
3. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
4. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
5. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion.
Huang W; Dong Z; Wang F; Peng H; Liu JY; Zhang JT
ACS Chem Biol; 2014 May; 9(5):1188-96. PubMed ID: 24661007
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.
Huang W; Dong Z; Chen Y; Wang F; Wang CJ; Peng H; He Y; Hangoc G; Pollok K; Sandusky G; Fu XY; Broxmeyer HE; Zhang ZY; Liu JY; Zhang JT
Oncogene; 2016 Feb; 35(6):783-92. PubMed ID: 26073084
[TBL] [Abstract][Full Text] [Related]
7. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
9. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
10. Novel activators and small-molecule inhibitors of STAT3 in cancer.
Yang L; Lin S; Xu L; Lin J; Zhao C; Huang X
Cytokine Growth Factor Rev; 2019 Oct; 49():10-22. PubMed ID: 31677966
[TBL] [Abstract][Full Text] [Related]
11. Highlighted STAT3 as a potential drug target for cancer therapy.
Lee H; Jeong AJ; Ye SK
BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
[TBL] [Abstract][Full Text] [Related]
12. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Beebe JD; Liu JY; Zhang JT
Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035
[TBL] [Abstract][Full Text] [Related]
13. Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.
Arpin CC; Mac S; Jiang Y; Cheng H; Grimard M; Page BD; Kamocka MM; Haftchenary S; Su H; Ball DP; Rosa DA; Lai PS; Gómez-Biagi RF; Ali AM; Rana R; Hanenberg H; Kerman K; McElyea KC; Sandusky GE; Gunning PT; Fishel ML
Mol Cancer Ther; 2016 May; 15(5):794-805. PubMed ID: 26873728
[TBL] [Abstract][Full Text] [Related]
14. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
Huang Q; Zhong Y; Dong H; Zheng Q; Shi S; Zhu K; Qu X; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2020 Feb; 187():111922. PubMed ID: 31810784
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
Haftchenary S; Avadisian M; Gunning PT
Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
17. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
[TBL] [Abstract][Full Text] [Related]
18. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
[TBL] [Abstract][Full Text] [Related]
19. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
Dong J; Cheng XD; Zhang WD; Qin JJ
J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
[TBL] [Abstract][Full Text] [Related]
20. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells.
Liu Y; Liu A; Xu Z; Yu W; Wang H; Li C; Lin J
Apoptosis; 2011 May; 16(5):502-10. PubMed ID: 21311975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
